Introduction
============

Drug prescribing patterns and clinical practices differ from country to country, but variation has also been observed among and within medical specialties. The differences are probably related to the needs of different patient populations, but they also reflect culture-specific and individual attitudes and forms of decision making among physicians \[[@B1]\]. Among developed countries, for example, Italy has one of the highest rates of antibiotic use \[[@B2]\]. Throughout the world, community use of these drugs appears to be significantly conditioned by patients\' demand and other social factors \[[@B1],[@B3]\]. These type of influences should be virtually nonexistent in intensive care units (ICUs), where antimicrobial therapy is usually prescribed empirically on the basis of limited evidence \[[@B4],[@B5]\]. When compared with general medical wards, ICUs displays higher rates of antimicrobial use because their patients are at higher risk for severe nosocomial infections \[[@B6],[@B7]\]. It has been estimated that over 50% of all critically ill patients will receive at least one antibiotic during their ICU stay, in most cases for pneumonia \[[@B8]-[@B10]\]. Widespread, often inappropriate, use of antimicrobials can favor the emergence of resistances \[[@B10],[@B11]\] and increase the occurrence of treatment failure, toxicity, mortality rates as well as the rise in the costs of care among critically ill patients \[[@B10],[@B12]\].

The aim of the present study was to characterize the current infection management practices in Italian ICUs, including the characterization of the antibacterial and antifungal drug regimens prescribed for various types of infections and the collection of evidence-based information support in the intensive care setting. We believe that the educational intervention programs carried out in Italy over the last few years by local professional associations have improved the infection control policies, the management practices, and the prescribing patterns in ICUs.

Materials and methods
=====================

Institutional review board approval was waived for this email-based survey since it did not involve collection of data on individual patients. The survey questionnaire was prepared by a panel of experts in the fields of intensive care, infectious diseases, pharmacology, and microbiology and endorsed by the Società Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva (SIAARTI, Italian Society of Anesthesia and Intensive Care) and organized in different sections. Section I focused on the ICU\'s characteristics (for example, location, number of beds, level of care, type of unit/hospital). Section II contained questions (mostly multiple-choice) on the approaches used to diagnose and treat infections (for example, use and characteristics of surveillance cultures, screening procedures) and infection management practices (for example, consultation of infectious disease specialists, access to antimicrobial susceptibility test, prescribing policies for antibiotics and antifungal drugs).

During the months of February and March 2011, the SIAARTI sent emails to all physicians working in the 450 ICUs located in public hospitals in Italy, inviting them to participate in the survey. The email explained the purpose of the survey, the information handling practices, and provided instructions for online completion of the questionnaire. Each ICU director who accepted the invitation was given password-controlled access to the survey and was responsible for collecting all the information from the physicians working in the unit to ultimately fill in one questionnaire reflecting the overall opinion and practices. Responses submitted between 30 April and 2 June 2011 were collected blindly into a central database and analyzed.

Submitted questionnaires were excluded from the analysis only if Section I had not been completed. Failure to answer one or more questions in Section II was not a cause for exclusion. In Section II, the frequency of each reported practice was calculated as a percentage of the total number of units that answered the question regarding that practice.

Results and discussion
======================

Characteristics of participating ICUs
-------------------------------------

As summarized in Table [1](#T1){ref-type="table"}, 175 of the 450 ICUs responded to the questionnaires, and they all met the inclusion criteria for data analysis (overall response rate: 38.8%). Seventy-five (43%) participating units were located in northern Italy, 56 (32%) in central Italy, and 44 (25%) in southern regions. Most were located in small (\< 500 beds, 54%) or medium-sized (500 to 1000 beds, 30%) hospitals. Sixty-three (36%) were at teaching hospitals. Eight-four percent were polyvalent ICUs, 13% were surgical units, and other unit types accounted for the remaining 3%. Most units (*n*= 163, 93%) contained four to twelve beds. The overall number of admissions per year varied from 80 to 1600, although in 63% of the units the range was much narrower (100 to 400 per year). The average ICU stay reported by respondents ranged from one to fifteen days (mean eight days).

###### 

Sample characteristics of the ICU center respondents.

  Response rate                                      175/450 (38.8%)
  -------------------------------------------------- -----------------
  **Geographical distribution of ICU respondents**   
                                                     
  Northern Italy                                     75/175 (43%)
  Central Italy                                      56/175 (32%)
  Southern Italy                                     44/175 (25%)
                                                     
  **Type of hospital**                               
                                                     
  Teaching hospital                                  63/175 (36%)
  Non-teaching hospital                              112/175 (64%)
                                                     
  **Hospital size**                                  
                                                     
  \< 500 beds                                        85/175 (49%)
  500-1000 beds                                      51/175 (29%)
  1000-1500 beds                                     15/175 (8%)
  \< 1500 beds                                       24/175 (14%)
                                                     
  **Type of ICU**                                    
                                                     
  Surgical                                           28/175 (16%)
  Mixed (Medical/surgical)                           147/175 (84%)
                                                     
  **Number of ICU beds**                             
                                                     
  1-6                                                77/175 (44%)
  7-10                                               58/175 (33%)
  11-18                                              33/175 (19%)
  19-50                                              7/175 (4%)

Infection control and management practices
------------------------------------------

Responses to infection control policies are summarized in Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. Table [1](#T1){ref-type="table"} shows responses to questions regarding practices and resources used for the diagnosis, prevention, and management of infections, which were answered by 146 to 162 of the 450 ICUs contacted (response rate from 32% to 36%). Information on routine empirical drug regimens used for specific types of infections is shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} (response rate from 32% to 38%). Table [3](#T3){ref-type="table"} shows how major antibacterial and antifungal drugs were prescribed in terms of doses, schedules, and methods of administration (response rate from 20% to 33%). The number, types, and location of the 175 units that took part in our survey are quite representative of the 450 ICUs that are present in our country. The characteristics of the participating units are also comparable to those documented in the annual report of the Italian Group for the Evaluation of Interventions in Intensive Care \[[@B13]\].

###### 

Infection control and management practices in participating ICUs.

  Practices                                                                                    Use - number (%)^a^
  -------------------------------------------------------------------------------------------- ---------------------
  Surveillance cultures                                                                        
   ○ on ICU admission                                                                          104/146 (71)
   ○ after ICU admission                                                                       128/146 (88)
                                                                                               
  Regular reports on antimicrobial resistance profiles of organisms isolated in the hospital   66/151 (41)
                                                                                               
  Automatic lab alerts when high-risk isolates are recovered^b^                                88/149 (59)
                                                                                               
  Nasal-swab screening for MRSA and decolonization when cultures are positive                  
   ○ Yes                                                                                       24/151 (16)
   ○ No                                                                                        103/151 (68)
   ○ In selected cases                                                                         24/151 (16)
                                                                                               
  Quantitative cultures of tracheobronchial secretions                                         108/156 (69)
                                                                                               
  Samples cultured to diagnose pneumonia                                                       
   ○ endotracheal aspirate                                                                     79/162 (49)
   ○ bronchoalveolar lavage fluid                                                              68/162 (42)
   ○ protected-specimen brush                                                                  15/162 (9)
                                                                                               
  Routine use of the Candida colonization index                                                44/148 (30)
                                                                                               
  Use of the procalcitonin assay                                                               100/152 (66)
                                                                                               
  Consultation of infectious disease specialists for infection management                      
   ○ Routinely                                                                                 16/149 (11)
   ○ In selected cases                                                                         82/149 (55)
   ○ Rarely                                                                                    36/149 (24)
   ○ No                                                                                        15/149 (10)
                                                                                               
  Use of antibiotic combinations for first-line empirical treatment of specific infections     
   ○ Community-acquired peritonitis                                                            92/162 (57)
   ○ Early-onset ventilator-associated pneumonia (VAP)                                         107/162 (66)
   ○ Late-onset ventilator-associated pneumonia (VAP)                                          142/162 (88)
   ○ Community-acquired pneumonia (CAP)                                                        113/162 (70)
   ○ Hospital-acquired pneumonia (HAP)                                                         128/162 (79)
   ○ Health-care-associated pneumonia (HCAP)                                                   138/162 (85)
   ○ Post-surgical peritonitis                                                                 133/162 (82)
   ○ Catheter-related bacteremia                                                               107/162 (66)
   ○ Purulent meningitis                                                                       120/162 (74)
                                                                                               
  Therapy de-escalation when culture results are back                                          109/162 (67)

^a^Denominators represent the number of ICUs that answered the specific question; ^b^high-risk isolates include MRSA, vancomycin-resistant enterococci, extended-spectrum beta-lactamase-producing gram-negative bacilli, *Candida*spp., and so on). MRSA, methicillin-resistant *Staphylococcus aureus*.

###### 

Antimicrobials most commonly used for empirical treatment of specific infections.

  ------------------------------------------------------------------------------------------------------------------------
  Infection/Drugs                      Frequency\          Infection/Drugs                             Frequency\
                                       **number (%)**^a^                                               **number (%)**^a^
  ------------------------------------ ------------------- ------------------------------------------- -------------------
  **Early VAP (\<5 days)**                                 **Suspected catheter-related bacteremia**   

  Piperacillin/tazobactam\             37/146 (25)\        Vancomycin\                                 70/171 (41)\
  Levofloxacin\                        25/146 (17)\        Piperacillin/tazobactam\                    21/171 (12)\
  Ceftriaxone                          19/146 (13)         Meropenem                                   15/171 (9)

                                                                                                       

  **Late VAP (≥5 days)**                                   **Suspected candidemia and/or invasive**    

  Piperacillin/tazobactam\             50/142 (35)\        **candidiasis**\                            97/151 (64)\
  Meropenem\                           23/142 (16)\        Fluconazole\                                32/151 (21)\
  Ceftazidime                          17/142 (12)         Caspofungin\                                9/151 (6%)
                                                           Voriconazole                                

                                                                                                       

  **Community-acquired pneumonia**                         **Community-acquired peritonitis**          

  Ceftriaxone\                         42/156 (27)\        Piperacillin/tazobactam\                    37/161 (23)\
  Levofloxacin\                        31/156 (20)\        Ampicillin/sulbactam\                       26/161 (16)\
  Amoxicillin/clavulanic acid          23/156 (15)         Cefotaxime                                  16/161 (10)

                                                                                                       

  **Hospital-acquired pneumonia**                          **Postoperative peritonitis**               

  Piperacillin/tazobactam\             51/171 (30)\        Piperacillin/tazobactam\                    63/165 (38)\
  Levofloxacin\                        26/171 (15)\        Meropenem\                                  46/165 (28)\
  Ceftriaxone                          22/171 (13)         Ertapenem                                   8/165 (5)

                                                                                                       

  **Health-care-acquired pneumonia**                       **Purulent meningitis**                     

  Piperacillin/tazobactam\             39/143 (27)\        Ceftriaxone\                                111/156 (71)\
  Meropenem\                           24/143 (17)\        Linezolid\                                  6/156 (4)\
  Ceftazidime                          13/143 (9)          Cefotaxime                                  6/156 (4)
  ------------------------------------------------------------------------------------------------------------------------

^a^Denominators represent the number of ICUs that answered the specific question. VAP, ventilator-associated pneumonia.

###### 

Most frequently used doses and schedules of antibiotic and antifungal drugs.

  ---------------------------------------------------------------------------------------------
  Drug/Administration                  Frequency\      Drug/Administration      Frequency\
                                       Number (%)^a^                            Number (%)^a^
  ------------------------------------ --------------- ------------------------ ---------------
  **Vancomycin**                                       **Ceftazidime**          

   TDD: 2 g                            104/142 (73)     TDD: 6 g                89/141 (63)

   Infusion: Continuous                122/142 (86)      3 g                    20/141 (14)

   Other: TDM                          94/142 (66)      Infusion: Continuous    68/141 (48)

                                                        Schedule: 3 doses/day   64/141 (45)

                                                                                

  **Teicoplanin**                                      **Ceftriaxone**          

   TDD: 400 mg                         43/110 (39)      TDD: 2 g                72/141 (51)

    800 mg                             32/110 (29)       4 g                    45/141 (32)

   Loading dose                        86/90 (96)       Schedule: 2 doses/day   78/141 (55)

                                                          Once daily            64/141 (45)

                                                                                

  **Piperacillin/tazobactam**                          **Cefepime**             

   TDD: 18.0 g                         61/148 (41)      TDD: 6 g                51/141 (36)

    13.5 g                             41/148 (28)       4 g                    28/141 (20)

   Infusion: Intermittent              61/148 (41)      Schedule: 3 doses/day   75/141 (53)

     Continuous                        55/148 (37)        2 doses/day           66/141 (47)

     Prolonged (3-4 hours)             33/148 (22)                              

                                                                                

  **Meropenem**                                        **Levofloxacin^b^**      

   TDD: 3 g                            62/138 (45)      TDD: 1000 mg            81/139 (58)

    6 g                                26/138 (19)       750 mg                 33/139 (24)

    Infusion: Prolonged intermittent   65/138 (47)      Schedule: 2 doses/day   90/139 (65)

     Intermittent infusion             55/138 (40)        Once daily            49/139 (35)

     Continuous infusion               18/138 (13)                              

                                                                                

  **Imipenem**                                         **Ciprofloxacin^b^**     

   TDD: 2 g                            66/135 (49)      TDD: 1200 mg            61/138 (44)

    3 g                                28/135 (21)       800 mg                 44/138 (32)

   Schedule: 4 doses/day               99/135 (73)      Schedule: 2 doses/day   70/138 (51)

     3 doses/day                       36/135 (27)        3 doses/day           68/138 (49)

                                                                                

  **Amikacin**                                         **Fluconazole**          

   TDD: 1 g                            65/120 (54)      TDD: 400 mg             77/137 (56)

    1.5 g                              13/120 (11)       800 mg                 25/137 (18)

   Schedule: Once daily                106/120 (88)     Schedule: Once daily    104/137 (76)

                                                          2 doses/day           33/137 (24)

                                                        Loading dose            114/137 (83)

                                                                                

  **Gentamicin**                                       **Voriconazole**         

   TDD: 240 mg                         35/120 (29)      TDD: 8 mg/kg            56/137 (41)

    160 mg                             18/120 (15)       4 mg/kg                27/137 (20)

   Schedule: Once a day                106/120 (88)     Loading dose            125/137 (91)

                                                                                

  **Daptomycin**                                       **Anidulafungin**        

   TDD: 6 mg/kg                        70/137 (51)      TDD: 100 mg             94/124 (76)

    8 mg/kg                            29/137 (21)      Loading dose            119/124 (96)

                                                                                

  **Linezolid**                                        **Caspofungin**          

   TDD: 1200 mg                        128/132 (97)     TDD: 50 mg              114/127 (90)

   Infusion: Intermittent              111/132 (84)     Loading dose            126/127 (99)

                                                                                

  **Tigecycline**                                      **Micafungin**           

   TDD: 100 mg                         130/134 (97)     TDD: 100 mg             105/128 (82)

   Schedule: 2 doses/day               133/134 (99)                             

   Loading dose                        131/134 (98)                             

                                                                                

  **Colistin**                                         **Amphotericin B**       

   Intravenous                                          TDD:                    

    TDD: 6,000,000 IU                  29/107(27)       Liposomal               

     9,000,000 IU                      27/107 (25)       3 mg/kg                61/127 (48)

    Schedule: 3 times/day              65/107 (61)       5 mg/kg                48/127 (38)

    Loading dose                       48/107 (45)      Lipid complex           

   Aerosol                                               5 mg/kg                54/101 (53)

    TDD: 3,000,000 IU                  36/107 (34)       3 mg/kg                29/101 (29)

     Schedule: 3 times/day             61/107 (57)                              
  ---------------------------------------------------------------------------------------------

^a^Denominators represent the number of ICUs that answered the specific question, ^b^levofloxacin and ciprofloxacin are the only fluoroquinolones available in Italy. TDD, total daily dose (intravenous unless otherwise stated); TDM, therapeutic drug monitoring.

Practices and resources used for the diagnosis, prevention, and management of infections
----------------------------------------------------------------------------------------

Although the importance of surveillance cultures for detecting carriers of drug-resistant microorganisms, improving nosocomial infection control, and guiding empirical antimicrobial treatment in ICUs has been documented \[[@B14],[@B15]\], there are conflicting opinions that routine surveillance cultures are indicated in critically ill patients \[[@B16]\].

In our study, we found that 88% of the participating units periodically performed surveillance cultures on all patients, and in 71% of cases the cultures were also collected on admission (Table [2](#T2){ref-type="table"}). Endotracheal and bronchial aspirates were the most frequently cultured specimens at both time points (92% and 90% of the units, respectively), which reflects a common concern among Italian intensivists of prevention and prompt detection of pneumonia. Regarding methicillin-resistant *Staphylococcus aureus*(MRSA) surveillance, although there are studies to support the use of active surveillance for high-risk patients \[[@B17],[@B18]\], there is not sufficient evidence to justify the mandatory use of this control measure \[[@B19]\]. Screening programs for MRSA colonization are expensive and, for certain authors, of dubious utility. Universal screening of large populations is not cost-effective, whereas targeted screening of high-risk populations may deserve additional study \[[@B20]\]. In our survey, two-thirds of the responding units never tested for MRSA colonization. This finding was consistent with the percentages of units that reported to collect nasal swabs at the time of the admission (46%) and after ICU admission (22%). Although the potential role of Candida colonization index for early detection of candidemia remains controversial, two recent Italian reports support the value of this tool \[[@B21],[@B22]\]. In the survey, we observed that very few units used the Candida colonization index during the patients\' admission assessment (3%), and fewer than 20% made regular use of the index after admission.

Over half of the participating sample (88 ICUs) received automatic alerts when multidrug-resistant (MDR) or sentinel microorganisms were isolated. The majority of the units were located in large and/or university hospitals in northern or central Italy. The geographic distribution of the hospitals that provided this service reflects regional rather than national rules. Access to information on local patterns of drug susceptibility was reported only in around 40% of the participating units. In roughly half of these cases (33/66), the data were updated every six (33%) or twelve (24%) months. Only three of the 66 ICUs mentioned (4.3%) had access to weekly updates. In our opinion, these reports need to be issued at least once a month, even if no MDR microorganisms have been isolated, to increase physicians\' awareness of the local microbial epidemiology. This seems particularly important in light of the low number \[16/149 (11)\] of units that regularly consulted an infectious disease specialist for advice on antimicrobial use (Table [2](#T2){ref-type="table"}). Two-thirds of the responding units reported the use of the procalcitonin assay. Although procalcitonin seems to be a valuable predictor of bacterial infections and an effective tool for reducing unnecessary antibiotic use \[[@B23],[@B24]\], its universal use in critically ill patients might have negative consequences \[[@B25],[@B26]\]. Around 67% of the centers reported using de-escalation strategies during antibiotic treatment. (In this case - and others - the possibility of discrepancies between self-perceived and actual behaviors cannot be excluded). Although a recent Cochrane review found insufficient evidence to recommend for or against antimicrobial de-escalation in adults with a diagnosis of sepsis \[[@B27]\], this strategy appears theoretically correct and capable of promoting therapeutic appropriateness.

Empirical antimicrobial regimens
--------------------------------

It is complex to comment on the appropriate use of empirical antibiotic therapy given the wide variation of resistance amongst different ICUs. However, the empirical regimens used in Italian ICUs to treat the most common infections appear - on the whole - appropriate, as summarized by Table [3](#T3){ref-type="table"}. It is noteworthy, however, that more than half the participating units (57% to 88%) used drug combinations rather than monotherapy for all types of infection (Table [2](#T2){ref-type="table"}) and, particularly, in cases of pneumonia and postoperative peritonitis. Several original reports and systematic reviews have raised questions regarding the benefits of combination therapy (which generally includes at least one beta-lactam antibiotic) for serious bacterial infections in immunocompetent and immunocompromised patients \[[@B28]-[@B30]\] .

The frequent use of vancomycin for suspected catheter-related bloodstream infections (41%) cannot be considered inappropriate. Nevertheless, increasing vancomycin minimum inhibitory concentrations (MICs) - recently defined as MIC creep - have indeed been documented in *S. aureus*isolates, but the impact of vancomycin MICs on outcomes is still being debated \[[@B31]\]. The rationale for treating these infections with piperacillin-tazobactam (reported in up to 12% of the ICUs) is questionable, since over 80% of these infections are caused by *Staphylococcus*spp \[[@B32]\].

The preferred drugs reported for community-acquired and postoperative peritonitis were beta-lactams (Table [3](#T3){ref-type="table"}). It is worth noting that in 50% of the participating units piperacillin/tazobactam, which has itself an excellent antianaereobic coverage, were used in association with another antianaerobic drug, metronidazole. In numerous studies, this type of redundant coverage has failed to improve clinical outcomes, and it is also associated with adverse effects and with selection of resistant strains \[[@B33]\].

The preferred first-line drug for invasive candidiasis was fluconazole (64%), followed by echinocandins (25%). Several consensus statements have been published on the treatment of candidemia and invasive candidiasis. The Infectious Diseases Society of America recommends fluconazole as a single antifungal agent or an echinocandin-based therapy \[[@B34]\]. Therefore, in 2011, the use of fluconazole was justified for stable patients, and echinocandins were also a reasonable choice in adults.

Inadequate or delayed antifungal therapy has significantly been linked to increased mortality \[[@B35]\], thus it is virtually impossible to reliably predict the nature or antimicrobial susceptibility of the causative *Candida*. For these reasons, starting an empirical treatment with fluconazole may have been considered inappropriate by many Italian clinicians.

Dosing, schedules, and administration
-------------------------------------

The data presented in Table [4](#T4){ref-type="table"} provide a picture of how antibiotics and antifungals are being administered in Italian ICUs. This is an important point since many of the pathophysiological changes associated with severe acute illness or sepsis (for example, increased capillary permeability, third spacing, increased volume of distribution, impaired renal and/or liver function) can affect antimicrobial pharmacokinetics (PK), especially those of drugs that are excreted renally (for example, beta-lactams, aminoglycosides, glycopeptides). Administration of these drugs to severely ill patients at dosages defined in studies conducted in healthy volunteers often produces suboptimal serum and tissue concentrations \[[@B36]\]. The method of administration is equally important. Beta-lactams, for example, are time-dependent antibiotics, and a time above MIC of 80% to 100% is required for maximum activity. Consequently, they are often administered via continuous or extended (3 to 4 h) infusion, an approach that improves efficacy and may also reduce the risk of inducing resistance \[[@B37]\].

In most units (132/148 - 89%), daily doses of piperacillin-tazobactam ranged from 13.5 to 18 g, and more than half the units (59%) infused the drugs over an interval longer than 3 to 4 hours. Compared with intravenous bolus delivery, extended infusion of this drug combination was recently shown to reduce mortality and shorten hospital stays in ICU patients with *Pseudomonas aeruginosa*infections \[[@B38]\]. Around 60% of the reporting units gave meropenem as a continuous or extended infusion. In critically ill patients at high risk for infections caused by resistant strains of gram-negative bacteria (*P. aeruginosa, Acinetobacter*), these approaches are more likely to achieve the optimal pharmacodynamic (PD) target \[[@B39]\] .

Several studies have emphasized the value of area under the curve (AUC)/MIC ratios for predicting the efficacy of glycopeptide-based regimens. The most commonly used daily doses of teicoplanin were 6 mg/kg and 12 mg/kg (corresponding to total daily doses of 400 and 800 mg, respectively) and almost all units (96%) administered a loading dose of this drug, which is important in ICU patients to ensure rapid achievement of therapeutically effective concentrations. Therapeutic drug monitoring (TDM) is strongly recommended during vancomycin therapy to optimize drug exposure and prevent toxicity \[[@B40]\]. Two-thirds of the ICUs monitored blood levels of vancomycin, which was usually administered as a continuous infusion (86%) (Table [3](#T3){ref-type="table"}). However, three-quarters of the units used standard daily dosages (2 grams) that are probably too low for critically ill patients. A recent PK/PD analysis of data for 191 ICU patients found that with standard vancomycin dosages the recommended AUC 0 to 24/MIC breakpoint for *S. aureus*is rarely achieved unless the patient has renal failure or is over 65 years of age. Otherwise, the daily dose needs to exceed 3 grams. This study also emphasized the need to consider agents other than vancomycin when methicillin-resistant or glycopeptide-intermediate *S. aureus*strains are involved \[[@B41]\].

For the aminoglycosides, which are concentration-dependent antibiotics, the efficacy target seems to be a maximum serum drug concentration (Cmax)/MIC ratio of 10 to 12 \[[@B42]\]. A single daily administration of 5 to 7 mg/kg of gentamicin is currently recommended, and a similar approach can be used with amikacin (15 to 20 mg/kg/day) \[[@B43]\]. It is important to recall that serum levels of aminoglycosides vary widely in critically ill patients, and increased volumes of distribution may result in suboptimal peak levels \[[@B44]\]. Almost all the participating units gave aminoglycosides once daily, but in light of the above findings, the most frequently reported doses (15 mg/kg/day and 3 to 5 mg/kg/day for amikacin and gentamicin, respectively) are probably too low to reach the optimal PK-PD target. In contrast, levofloxacin and ciprofloxacin (the only fluoroquinolones available in Italy) were generally used at maximum recommended daily doses: levofloxacin 1000 mg (58%) in two doses or 750 mg (25%) in a single daily dose; ciprofloxacin 1200 mg (44%) or 800 mg (32%) in two to three doses. These regimens should produce an AUC/MIC ratio of about 125, which correlates with good microbiological and clinical outcomes in critically ill patients \[[@B45]\].

Colistin has recently re-emerged as a last-resort treatment for MDR gram-negative bacterial infections. In several PK-PD studies, its effects have proved to be concentration-dependent, and AUC/MIC and Cmax/MIC ratios are probably the factors correlated with outcome \[[@B46],[@B47]\]. Around half the participating centers appear to be using this drug according to the more recent literature in terms of daily doses (6 to 9 million IUs in 52% of the cases) and after the administration of a loading dose (45%) (Table [4](#T4){ref-type="table"}).

Almost all ICUs administered a fixed dose of tigecycline (100 mg loading dose followed by 50 mg every 12 h). Regarding daptomycin, preliminary evidence suggests that doses exceeding 6 mg/kg/day may be associated with more favorable outcomes \[[@B48]\]. Around 21% of the ICUs reported daptomycin doses exceeding the approved range (4 to 6 mg/kg/day).

Analysis of antifungal drug-prescribing practices revealed that most ICUs used appropriate daily and loading doses of both the azoles and echinocandins. However, in 38% of the participating units, liposomal amphotericin B was administered at a daily dose of 5 mg/kg despite clear evidence that doses above 3 mg/kg/day do not have an increased efficacy in the treatment of invasive fungal infections \[[@B49]\]. Furthermore, roughly 20% of the units reported using fluconazole at a daily dose of 12 mg/kg. This is a much higher dose than the one recommended by standard guidelines, and even when it is administered empirically in a critically ill patient with unexplained fever and a high risk for invasive candidiasis, it is unjustified and inappropriate \[[@B34]\].

TDM is indicated for many azoles (especially itraconazole, voriconazole, and posaconazole) \[[@B50]\]. Blood levels of antifungal drugs are characterized by broad, unpredictable variability related to multiple factors, including patients\' age, genetic background, compliance, gastrointestinal function, use of co-medications, and liver and/or renal dysfunction \[[@B45]\]. Negative outcomes are associated with both antifungal underdosing (treatment failure) and overdosing (toxicity) \[[@B50]\]. Unfortunately, real-time measurement of antifungal drug blood levels is not routinely available, which may explain why voriconazole TDM was not mentioned by our ICUs.

Our study has several limitations. First of all, our questionnaire did not by any means explore all aspects of infection control. Second, although the sample surveyed is representative of the Italian ICUs, the overall response rate was less than 40%, with even lower response rates in certain questions. This raises the possibility of a selection bias toward ICUs that are more concerned with the efficacy of their infection management policies and procedures. Third, all of our data reflect self-reported behavior that may or may not coincide with actual practices, and physicians often tend to overestimate their use of recommended practices (tests, procedures, drug regimens) \[[@B51]\]. Given the last two considerations, certain problematic areas in the ICU setting may have escaped our detection. On the other hand, however, those that did emerge are likely to be realistic, and they may even underestimate more serious and widespread issues.

Our survey indicates that certain resources and tools for infection control are being underused in Italian ICUs, including MRSA screening and updated reports on local microbial epidemiology. As for antimicrobial drug therapy, prescribing practices were generally appropriate, but certain aspects deserve closer investigation, above all the widespread preference for multidrug empirical regimens, which in some cases seemed difficult to justify. Furthermore, certain antibiotics were reportedly used at doses unlikely to achieve PK/PD targets in critically ill patients, whereas inappropriately high doses were reported for certain antifungal drugs. There is little evidence that practices of this type can be corrected by guidelines, restrictive formularies, or other administrative measures, probably because they usually stem from a lack of information \[[@B52]\]. Our findings will hopefully serve to stimulate Italian ICUs to critically review their own infection management policies with the aim of reinforcing the strong points and correcting practices likely to be less effective.

Conclusions
===========

In this study, although infection control policies and management practices are generally appropriate in Italian ICUs, certain aspects, such as the extensive use of multidrug empirical regimens and the inappropriate antimicrobial dosing, deserve careful management and closer investigation.

Key messages
============

• Considering the number, types, and locations of the 175 units that took part in our survey, the sample is quite representative of Italy\'s 450 ICUs.

• The majority of the participating units periodically performed surveillance cultures on and after admission.

• Empirical antimicrobial drug regimens for specific infections were generally appropriate. Combination therapy was preferred over monotherapy (sometimes without clear justification), and around 70% of the centers reported using de-escalation strategies during the treatment phase.
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